Abstract
Background and Aim of Work
Pancreatic cancer is the deadliest of the 21 most common cancers, largely because it is often identified at a late stage, we aimed to determine the control rates, and PFS for patients who received docetaxel-oxaliplatin regimen as a 2nd line therapy.
Patients and Methods
Twenty-five patients with advanced cancer pancreas progressed or failed on 1st line treatments and justified the inclusion criteria were eligible to receive Docetaxel 75 mg/m2 over 1h iv infusion on day 1, Oxaliplatin 80 mg/m2 over 2 h iv infusion on day 2, the cycle was repeated every 3 weeks for 6-8 cycles unless disease progression or severe toxicity appeared.
Results
No patients achieved complete response (CR), and the control rate (control rate = partial response (PR = 6/25, 24%) + stable disease (SD = 9/25, 36%) was 60% while disease progression (DP) was demonstrated in (10/25) 40% of patients, the median PFS was 7 ± 0.777 ms (95% confidence interval: 5.467-8.524 ms), grade 3 neutropenia, fatigue, diarrhea, and vomiting were developed in 12%, 8%, 12% and 8% of patients respectively.
Conclusions
Docetaxel-oxaliplatin regimen was an active regimen in advanced cancer pancreas based on our encouraging results without occurrence of grade four toxicities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Cancer Society, 2015; SEER, 2015.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28(10):1645–51.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil versus gemcitabine refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423–9.
Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676–81.
Gill S, Ko YJ, Cripps MC, BeauDOIn A, Dhesy-Thind SK, Zulfiqar M. PANCREOX: a randomised phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT) J Clin Oncol. 2014;32:abstr 4022.
Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res. 2010;30:2905–9.
Ettrich TJ, Perkhofer L, von Wichert G, Gress TM, Michl P, Hebart HF, et al. A phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer. 2016;16:21. https://doi.org/10.1186/s12885-016-2052-4.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rayan, A., Abdel Fattah, O.N., Soliman, A. et al. Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma. J Gastrointest Canc 50, 519–524 (2019). https://doi.org/10.1007/s12029-018-0116-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-018-0116-1